Screener
Supernus Pharmaceuticals SUPN Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Supernus Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
FAQ
- What is Supernus Pharmaceuticals's debt-to-equity?
- Supernus Pharmaceuticals (SUPN) reported debt-to-equity of 0× in Q1 2026.
- How has Supernus Pharmaceuticals's debt-to-equity changed year-over-year?
- Supernus Pharmaceuticals's debt-to-equity increased by 21.4% year-over-year, from 0× to 0×.
- What is the long-term trend for Supernus Pharmaceuticals's debt-to-equity?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's debt-to-equity has grown at a -13.7% compound annual growth rate (CAGR), from 0.1× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Supernus Pharmaceuticals's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude